IP Library › Granted Patent US 10,597,436
Granted Patent B2
US 10,597,436 · App. 16/529,095 · Granted Mar 24, 2020

Acylated insulin compound

Inventors: Wen Liu (Carmel, IN); Adam Robert Mezo (San Diego, CA); Francisco Alcides Valenzuela (Indianapolis, IN)
Assignee: Eli Lilly and Company
C07K14/62A61K47/542A61K47/65A61P3/10A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,597,436
App. No.
16/529,095
Granted
Mar 24, 2020
Kind
B2
Abstract

The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.

Claims (1)

1. A compound having the formula:

Continuity (3)
Division 15983167 · May 18, 2018
Provisional Application 62511690 · May 26, 2017
Related Publication 20190345215A1 · Nov 14, 2019